论文部分内容阅读
阿卡波糖(acarbose)是一类新型口服抗高血糖药物,具有良好的降低血糖作用,尤以对餐后血糖。我们自1995年在应用阿卡波糖之始即对其不良反应进行监测。 病例为我院门诊及住院病人,凡服用阿卡波糖者为观察之对象,观察期限为12周。共观察1002例。其中Ⅰ型糖尿病24例,Ⅱ型糖尿病880例,糖耐量降低(IGT)98
Acarbose is a new class of oral anti-hyperglycemic drugs with good hypoglycemic effects, especially on postprandial blood glucose. We have monitored adverse reactions since 1995 at the start of acarbose. Cases for our hospital outpatient and inpatient, who take acarbose for the observation of the object, the observation period of 12 weeks. A total of 1002 cases were observed. Among them, 24 cases were type I diabetes mellitus, 880 cases were type II diabetes mellitus, with impaired glucose tolerance (IGT) 98